articleTop 1% cited

Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

Ophthalmology · 2013 · Vol. 121(1) · pp. 193–201

Ursula Schmidt‐Erfurth✉(Medical University of Vienna)Peter K. Kaiser(Cleveland Eye Clinic)Jean‐François Korobelnik(Centre Hospitalier Universitaire de Bordeaux)David M. Brown(Retina Consultants of Houston)Victor Chong(University of Oxford)Quan Dong Nguyen(Johns Hopkins University)Allen C. Ho(Wills Eye Hospital)Yuichiro Ogura(Nagoya City University)Christian Simader(Medical University of Vienna)Glenn J. Jaffe(Duke University)Jason S. Slakter(Vitreous Retina Macula Consultants of New York)George D. Yancopoulos(Regeneron (United States))Neil Stahl(Regeneron (United States))Robert Vitti(Regeneron (United States))Alyson J. Berliner(Regeneron (United States))Yuhwen Soo(Regeneron (United States))Majid Anderesi(Bayer (Germany))Olaf Sowade(Bayer (Germany))Oliver Zeitz(Universität Hamburg)Christiane Norenberg(Bayer (Germany))Rupert Sandbrink(Heinrich Heine University Düsseldorf)Jeffrey S. Heier(Tufts University)

View via DOI Publisher page

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic ConditionsAfliberceptMedicineMacular degenerationRanibizumabDosingVisual acuityOphthalmologyPro re nataRandomized controlled trialConfidence interval

MeSH terms

RanibizumabAgedDouble-Blind MethodDrug CombinationsFemaleFluorescein AngiographyHumansMaleRecombinant Fusion ProteinsRetinaVisual AcuityTreatment OutcomeRetreatmentAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth Factor